LISBON, Portugal, March 5, 2013 /PRNewswire/ — Biosurfit, a rapidly-growing company focused on the Point of Care medical diagnostic market, is pleased to announce today the appointment of Dr. Ian Gilham as Chairman of the Board.
Previously, Dr. Ian Gilham was Chief Executive Officer of Axis-Shield plc, the in-vitro diagnostics company acquired by Alere in November 2011 for £235M. Whilst at Axis-Shield, Dr. Gilham held the position of Chief Operating Officer and became Chief Executive Officer in January 2008. Prior to its sale to Alere, Axis-Shield’s revenues rose above £100M and the company issued a maiden dividend. Before joining Axis-Shield, Dr. Gilham was VP Pharmacogenetics at GSK where he was responsible for the delivery of pharmacogentic tests, as well as novel diagnostic tests used in targeting GSK’s medicines. Prior to joining GSK, Dr. Gilham held international general management, marketing, business development and R&D positions with Abbott Laboratories, Celltech and Amersham, gaining wide expertise in the fields of pharmaceuticals and clinical diagnostics.
Commenting on his appointment, Dr. Ian Gilham , said: “I am delighted to join Biosurfit as Chairman of the Board. It is an incredibly exciting time for the company with new opportunities ahead and a chance to support an entrepreneurial team that have developed innovative and potentially game changing technologies into a great new product. Biosurfit has a tremendous potential in Point of Care Diagnostics with its spinit® instrument that is due to be launched in 2013. I look forward to working with the team to help Biosurfit in reaching its great ambitions.”